Sky Century Investment (SKYI) Return on Capital Employed (2025 - 2026)
Sky Century Investment's (SKYI) quarterly Return on Capital Employed came in at 26.28% in Q2 2026, down 350.0% year-on-year from 10.51% in Q2 2025, and up 12.84% on a QoQ basis from 23.29% in Q1 2026.
Sky Century Investment (SKYI) Return on Capital Employed (2025 - 2026) Analysis & Trends
Sky Century Investment (SKYI) has 2 years of Return on Capital Employed data on file, last reported at 26.28% in Q2 2026.
- On a quarterly basis, Return on Capital Employed fell 350.0% year-over-year to 26.28% in Q2 2026; TTM through May 2026 was 26.28%, a 350.0% decrease from a year earlier, with the FY2025 full-year figure at 39.69%, up 992.0% from the prior year.
- Return on Capital Employed for Q2 2026 stood at 26.28%, up from 23.29% in the prior quarter.
- Over the last five years, Return on Capital Employed for SKYI reached as high as 41.75% in Q3 2025 and fell as low as 23.29% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Sky Century Investment | 1.06 Mn | 1.06 Mn | 26,045.00 | 26.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 26.28% |
| Feb 28, 2026 | 23.29% |
| Nov 30, 2025 | 32.95% |
| Aug 31, 2025 | 41.75% |
| May 31, 2025 | 29.78% |